Disclosure SP has received honoraria and consultant fees from AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, Novartis, Takeda, Bristol Myers Squibb (BMS), Merck Sharp & Dohme (MSD), EMD Serono, Bayer, Blueprint, Daiichi Sankyo, Guardant Health, Janssen, GlaxoSmithKline (GSK), BeiGene, Incyte, Eli Lilly, Seattle Genetics and Amgen; received institutional research funding from AstraZeneca, Roche, Boehringer Ingelheim, Clovis, Celgene, Novartis, Takeda, Ariad, BMS, MSD, Daiichi Sankyo, Guardant Health, Janssen, Epizyme, GSK, Mirati, Trizel and Turning Point Therapeutics. PB has received institutional research funding from AstraZeneca, BMS and MSD; holds non-remunerated consulting and advisory board roles for BMS, MSD, Pfizer, Epizyme, Trizel and Daiichi. IO holds an advisory board role for AstraZeneca; has received speakers fee from Roche and an institutional research grant from Medtronic and Roche. AS has an advisory board role for BMS, MSD, AstraZeneca and Roche and has received an institutional research grant from BMS. CFF has received institutional honoraria from AstraZeneca and institutional research funding from AstraZeneca and Elekta. AGN has received honoraria and consultant fees from Merck, BMS, AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, Novartis, Eli Lilly, AbbVie and Oncologica; has received institutional research funding from Pfizer and has produced educational content for AstraZeneca, Pfizer, UpToDate and European Society of Oncology. NG has received honoraria and consultant fees from AstraZeneca, Boehringer Ingelheim, BMS, Lilly, MSD, Roche and Trizell; has received institutional research funding from AstraZeneca, Boehringer Ingelheim, BMS, Lilly, MSD, Roche and Trizell; has received hospitality/travel expenses from AstraZeneca, BMS, Roche and has an immediate family member who is an employee of AstraZeneca. AKN has received honoraria and consultant fees from AstraZeneca, Boehringer Ingelheim, MSA Pharma, Trizell, Roche, Douglas Pharmaceuticals, Atara Biotherapeutics, Seagen, PharmAbcine, BMS and UpToDate; has received institutional research funding from AstraZeneca and Douglas Pharmaceuticals. MR has received honoraria for consultancy and lectures from Amgen, AstraZeneca, BMS, Boehringer-Ingelheim, Merck, Mirati, MSD, Lilly, Novartis, Pfizer, Regeneron, Roche and Sanofi Bioepis.